A Novel, Pleiotropic Oral Drug Class that Blocks Gut Migration of Activated T Cells
Time: 2:30 pm
day: Day One
Details:
- Antagonists to retinoic acid receptor-alpha (RARα) block upregulation of α4β7 and CCR9 during T cell activation in mesenteric lymph nodes
- Inflammatory damage to mucosal epithelia is significantly inhibited in colitis and related disease models by concomitant daily oral dosing of an RARα antagonist
- Preclinical safety findings for the highly selective RARα antagonist OR-812 support further development
